Press Releases

Press Releases

or

June 3, 2013
BeiGene and Merck KGaA, a top big pharma company have entered into a global licensing, co-development, co-promotion and commercialization agreement for BeiGene-283. The compound is a second-generation BRAF inhibitor for the treatment of cancer. BeiGene-283,which is currently in preclinical
June 1, 2013
BeiGene, a Beijing biopharma startup, out-licensed the ex-China rights for a pre-clinical cancer drug to Merck Serono, the drug discovery arm of Germany’s Merck KGaA (Xetra: MRK). To date, BeiGene has been in the news for acquiring China rights to western-developed drugs.
May 31, 2013
Merck Serono has signed a global licensing, co-development and commercialisation agreement with Chinese biotech BeiGene, for a cancer compound called BeiGene-283. The second-generation BRAF inhibitor is currently in preclinical development. BRAF inhibitors target a protein that is a downstream
May 30, 2013
BEIGENE announced today John Gong, Vice President of Drug Development and Regulatory Affairs of BeiGene will attend ChinaBio Partnering Forum 2013 from May 29-30 in Shangri-La Hotel, Beijing, China. For further information, please contact: pr@beigene.com.
May 17, 2013
BEIGENE announced today John V. Oyler, Founder and Chief Executive Officer of BeiGene as well as our senior management team will attend 2013 ASCO from May 31-June 4 in McCormick Place, Chicago, USA. For further information, please contact: pr@beigene.com About BeiGene BeiGene is a Chinese life
May 12, 2013
BEIGENE announced today John Gong, Vice President of Drug Development and Regulatory Affairs of BeiGene will attend 2013 DIA from May 12-15 in Beijing International Convention Center, China. For further information, please contact: pr@beigene.com. About BeiGene BeiGene is a Chinese life sciences
April 8, 2013
BEIGENE announced today John V. Oyler, Founder and Chief Executive Officer of BeiGene will attend 2013 Bio from April 22 – 25, in Chicago, USA. For further information, please contact: pr@beigene.com About BeiGene BeiGene is a Chinese life sciences biotechnology company based in the ZhongGuanCun